Associations of Haplotypes Upstream of IRS1 with Insulin Resistance, Type 2 Diabetes, Dyslipidemia, Preclinical Atherosclerosis, and Skeletal Muscle LOC646736 mRNA Levels
Table 1
Clinical characteristics of SAPHIR participants without diabetes mellitus by haplotypes.
Trait
Haplotypes
1111
1112
1121
1221
2112
2221
Frequencies
0.169
0.397
0.029
0.014
0.029
0.322
Age, years
25.7 (25.2–26.1)
26.1 (25.8–26.4)
25.1 (23.8–26.4)
26.1 (24.3–28.0)
25.8 (24.7–26.9)
25.7 (24.4–26.1)
n.s.
BMI,
11.9 (10.9–12.8)
11.9 (10.9–12.8)
11.9 (10.7–13.1)
12.0 (10.4–13.5)
11.8 (10.5–13.0)
11.9 (10.9–12.8)
n.s.
Lean body mass, kg(2)
45.2 (43.3–47.1)
45.3 (43.5–47.0)
45.0 (42.6–47.4)
46.0 (42.7–49.4)
45.9 (43.4–48.4)
45.2 (43.4–47.0)
n.s.
Fat mass, kg(2)
1.81 (−0.21–3.84)
2.01 (0.00–4.01)
2.46 (−0.12–5.05)
0.69 (−2.45–3.83)
1.00 (−1.54–3.54)
2.09 (0.09–4.08)
n.s.
Body fat, %(2)
−0.4 (−2.3–1.4)
−0.2 (−2.0–1.6)
0.2 (−2.5–2.8)
−1.9 (−4.8–1.0)
−1.6 (−3.9–0.7)
−0.1 (−1.9–1.7)
n.s.
VAT,
1.2 (−9.6–12.1)
4.5 (−5.8–14.9)
4.0 (−9.6–17.6)
6.7 (−8.8–22.3)
−0.2 (−14.0–13.5)
5.7 (−4.6–16.1)
n.s.
SAT,
17.9 (−5.7–41.6)
16.4 (−6.7–29.6)
27.3 (−2.1–56.6)
26.2 (−10.3–62.6)
17.2 (−12.6–47.0)
19.2 (−3.4–41.9)
n.s.
VAT/SAT(2)
0.18 (0.13–0.23)(3)
0.20 (0.15–0.25)
0.18 (0.11–0.25)
0.19 (0.10–0.28)
0.17 (0.10–0.24)
0.20 (0.15–0.25)
n.s.
Glucose, mg/dL(5)
30.6 (27.8–33.4)
30.9 (28.2–33.6)
30.8 (26.8–34.9)
31.9 (26.9–37.1)
29.1 (26.1–32.1)
30.8 (28.1–33.6)
n.s.
Insulin, pmol/L(5)
−31 (−38–−24)
−30 (−36–−23)
−31 (−39–−22)
−24 (−32–−16)(3)
−30 (−38–−23)
−32 (−39–−26)(3)
0.0562
HOMA-IR(5)
−1.46 (−1.76–−1.17)
−1.41 (−1.69–−1.13)
−1.45 (−1.80–−1.10)
−1.14 (−1.49–−0.79)(4)
−1.45 (−1.77–−1.13)
−1.52 (−1.80–−1.23)(4)
0.0293
Cholesterol, mg/dL(5)
80 (69–91)
80 (69–91)
74 (61–87)
89 (73–104)
77 (63–91)
79 (68–90)
n.s.
HDL chol, mg/dL(5)
36 (32–40)
36 (32–39)
34 (29–39)
37 (30–43)
36 (31–41)
37 (33–41)
n.s.
LDL chol, mg/dL(5)
51 (40–61)
50 (40–61)
43 (30–55)
57 (43–71)
45 (32–58)
49 (39–60)
n.s.
Triglycerides, mg/dL(5)
−3 (−27–22)
2 (−22–26)
4 (−22–31)
−5 (−48–37)
3 (−28–34)
−4 (−29–21)(3)
n.s.
CRP, mg/L(5)
−2.58 (−3.29–−1.88)(3)
−2.39 (−3.05–−1.72)
−2.40 (−3.27–−1.52)
−2.40 (−3.46–−1.34)
−2.51 (−3.39–−1.63)
−2.56 (−3.24–−1.87)(4)
n.s.
Results represent expected means (95% CI) of untransformed data; for haplotype designation, 1 or 2 refers to the major or minor alleles, respectively, in the following order: rs7578326, rs2943634, rs2943641, and rs2713538. (1) values for global haplotype effect, (2)adjusted for age and sex, (3) and (4), relative to the most frequent haplotype, (5)adjusted for age, sex, and BMI, , for lipids (subjects on lipid lowering drugs excluded). for body composition, for VAT and SAT, and for CRP (subjects with values >20 mg/L excluded); n.s., not significant; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue.
